Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2), also known as fibulin-4, is a member of the fibulin family of extracellular matrix proteins. EFEMP2 is essential for the assembly of elastic fibers, providing a scaffold that coordinates cross-linking of elastin by interacting with tropoelastin, lysyl oxidase, and fibrillin-1. It is critical for connective tissue integrity, especially in tissues rich in elastic fibers such as blood vessels, lungs, and skin. Loss-of-function mutations in EFEMP2 result in autosomal recessive cutis laxa type 1B (ARCL1B), which is characterized by loose skin, pulmonary emphysema, and severe cardiovascular defects, including aortic aneurysm. Its functions extend to collagen maturation and regulation of smooth muscle cell differentiation, underscoring its central role in extracellular matrix formation and vascular stability[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2).